+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Crizotinib Drugs Market - Global Forecast 2025-2030- Product Image
Crizotinib Drugs Market - Global Forecast 2025-2030- Product Image
Sale

Crizotinib Drugs Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6129630
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior leaders navigating the evolving oncology landscape recognize that access, innovation, and supply chain resiliency are crucial for sustaining competitive advantage in the crizotinib market. This comprehensive report delivers a strategic assessment designed for decision-makers seeking to optimize portfolio strategies, capitalize on emerging technologies, and respond proactively to regulatory shifts influencing targeted cancer therapies.

Market Snapshot: Crizotinib Market Overview

The global crizotinib market is transforming due to rapid advancements in molecular diagnostics, ongoing regulatory changes, and the increasing adoption of precision oncology across major regions. Market growth is shaped by the pivotal role crizotinib plays in treating ALK-positive and ROS1-positive non-small cell lung cancer, reinforced by evolving clinical guidelines and a distinct movement toward patient-tailored therapy. Rising investments in companion diagnostics and digital health platforms, coupled with expanding access initiatives, create a dynamic competitive environment for both originator and generic formulations. Strategic partnerships, resilient supply chain models, and diversified channel strategies further support robust market expansion and stable patient access, distinguishing leading stakeholders in the current landscape.

Scope & Segmentation of the Crizotinib Market

  • Competitive Landscape: Brand and generic crizotinib suppliers navigating variable patent timelines and region-specific pricing strategies.
  • Indications: Segmented by ALK-positive and ROS1-positive patient groups with differentiated clinical management pathways.
  • Dosage Strengths: Analysis of 200 mg and 250 mg regimens highlights prescriber preferences shaped by safety and tolerance profiles.
  • Distribution Channels: Inclusion of hospital pharmacies, online pharmacies, retail chain pharmacies, and independent outlets; each influences patient access and inventory process complexity.
  • End Users: Clinics, homecare providers, government and private hospitals, diagnostic, and oncology centers; segmentation enhances insights into diverse care delivery models.
  • Patient Age Groups: Adult and pediatric cohorts, reflecting distinct pharmacokinetics and tailored administration guidelines.
  • Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina); Europe, Middle East, and Africa (including United Kingdom, Germany, France, and more); Asia-Pacific (China, India, Japan, and additional key territories).
  • Leading Companies: Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Dr. Reddy’s Laboratories Limited, Natco Pharma Limited, Lupin Limited, Hetero Laboratories Limited, and Sandoz International GmbH.

Key Takeaways for Senior Decision-Makers

  • Crizotinib’s integration within precision medicine is driving uptake in both established and emerging healthcare systems, with refined molecular stratification supporting more personalized clinical pathways.
  • Technological innovations like next-generation sequencing and liquid biopsy are accelerating first-line treatment deployment while simplifying real-world patient identification and monitoring.
  • Strategic collaborations between research institutions, healthcare providers, and industry players facilitate streamlined product distribution and broader access, particularly where infrastructure is variable.
  • Brand-generic competition and alternative crystalline forms are shaping cost-containment strategies, ensuring affordability within price-sensitive geographies post-patent expiry.
  • End-user preferences for distribution models directly influence stocking practices, care setting adaptation, and the development of integrated patient support programs.

Tariff Impact: Navigating Tariff Adjustments and Supply Chain Complexity

The 2025 United States tariff adjustments have created cost volatility in crizotinib supply chains, especially for manufacturers reliant on imported active pharmaceutical ingredients. Executive responses include dual-sourcing strategies, shift to domestic suppliers, and investment in localized synthesis and regional hubs. While some organizations absorb increased costs via productivity improvements, tariff relief initiatives and regulatory collaborations remain essential for maintaining uninterrupted medicine availability and mitigating pricing pressures at the provider and patient level.

Crizotinib Market Methodology & Data Sources

This research employs a robust methodology, combining primary interviews with oncology and regulatory experts, with secondary analysis from peer-reviewed literature, corporate disclosures, and industry reports. Statistical techniques and thematic coding inform in-depth segment assessment. Triangulation ensures consistency and strengthens result validity. Industry-accepted ethical standards guide confidentiality and data integrity throughout the study.

Why This Report Matters

  • Offers actionable intelligence for executives planning investments in diagnostics, localized manufacturing, or strategic collaborations to sustain crizotinib access.
  • Supports informed decisions on portfolio management, pricing strategies, and market entry by leveraging comprehensive market, segment, and competitor insights.
  • Equips teams to navigate regulatory disruptions, anticipate tariff impacts, and unlock value through operational resilience and digital health integration.

Conclusion

This report delivers a concise, data-driven foundation for optimizing crizotinib market strategies across technology, supply, and regional dimensions. Use these insights to shape future decisions, drive stakeholder alignment, and strengthen your organization’s position in targeted oncology therapeutics.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Patent expiry of crizotinib leading to increased generic competition and pricing pressure
5.2. Emergence of next generation ALK inhibitors challenging crizotinib as first line treatment for ALK positive NSCLC
5.3. Real world evidence supporting expanded crizotinib usage in pediatric ALCL patients with ALK rearrangements
5.4. Strategic partnerships for development of crizotinib combination therapies to overcome ALK inhibitor resistance
5.5. Integration of companion diagnostics for ALK and ROS1 mutations driving personalized crizotinib treatment protocols
5.6. Regulatory approvals for crizotinib in ROS1 positive cancers expanding off label prescription trends
5.7. Pricing strategies and reimbursement policies reshaping market access for crizotinib in emerging economies
5.8. Competitive pressure from novel targeted therapies such as lorlatinib and brigatinib impacting crizotinib uptake
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Crizotinib Drugs Market, by Competitive Landscape
8.1. Introduction
8.2. Brand
8.3. Generic
9. Crizotinib Drugs Market, by Indication
9.1. Introduction
9.2. Alk Positive
9.3. Ros1 Positive
10. Crizotinib Drugs Market, by Dosage Strength
10.1. Introduction
10.2. 200 Mg
10.3. 250 Mg
11. Crizotinib Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
11.4.1. Chain Pharmacy
11.4.2. Independent Pharmacy
12. Crizotinib Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Homecare
12.4. Hospitals
12.4.1. Government Hospitals
12.4.2. Private Hospitals
12.5. Specialty Centers
12.5.1. Diagnostic Centers
12.5.2. Oncology Centers
13. Crizotinib Drugs Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Pediatric
14. Americas Crizotinib Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Crizotinib Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Crizotinib Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. Viatris Inc.
17.3.3. Teva Pharmaceutical Industries Ltd.
17.3.4. Sun Pharmaceutical Industries Limited
17.3.5. Cipla Limited
17.3.6. Dr. Reddy’s Laboratories Limited
17.3.7. Natco Pharma Limited
17.3.8. Lupin Limited
17.3.9. Hetero Laboratories Limited
17.3.10. Sandoz International GmbH
18. ResearchAI19. ResearchStatistics20. ResearchContacts21. ResearchArticles22. Appendix
List of Figures
FIGURE 1. CRIZOTINIB DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CRIZOTINIB DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CRIZOTINIB DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CRIZOTINIB DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CRIZOTINIB DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. CRIZOTINIB DRUGS MARKET: RESEARCHAI
FIGURE 28. CRIZOTINIB DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 29. CRIZOTINIB DRUGS MARKET: RESEARCHCONTACTS
FIGURE 30. CRIZOTINIB DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CRIZOTINIB DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY BRAND, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY BRAND, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY ALK POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY ALK POSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY ROS1 POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY ROS1 POSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY 200 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY 200 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY 250 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY 250 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CRIZOTINIB DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS CRIZOTINIB DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES CRIZOTINIB DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 109. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 110. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 111. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 112. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 113. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 114. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 115. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 118. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 119. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 122. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 123. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 124. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 125. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 126. CANADA CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 127. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 128. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 129. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 130. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 131. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 132. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 133. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 136. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 137. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 140. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 141. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 142. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 143. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 144. MEXICO CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA CRIZOTINIB DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 219. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 220. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 221. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 224. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 225. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 228. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 229. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 232. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 233. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 234. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 235. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 236. GERMANY CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 237. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 238. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 239. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 240. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 241. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 242. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 243. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 246. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 247. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 250. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 251. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 252. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 253. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 254. FRANCE CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 273. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 274. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 275. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 278. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 279. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 282. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 283. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 286. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 287. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 288. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 289. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 290. ITALY CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 291. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 292. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 293. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 294. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 295. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 296. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 297. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 300. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 301. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 304. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 305. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 306. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 307. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 308. SPAIN CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 327. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2018-2024 (USD MILLION)
TABLE 328. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY COMPETITIVE LANDSCAPE, 2025-2030 (USD MILLION)
TABLE 329. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 330. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 332. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 333. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 334. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 335. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 336. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 337. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 338. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 339. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 340. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 341. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
TABLE 342. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2025-2030 (USD MILLION)
TABLE 343. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 344. SAUDI ARABIA CRIZOTINIB DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 345.

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Crizotinib Drugs Market report include:
  • Pfizer Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Limited
  • Cipla Limited
  • Dr. Reddy’s Laboratories Limited
  • Natco Pharma Limited
  • Lupin Limited
  • Hetero Laboratories Limited
  • Sandoz International GmbH

Related Topics

Related Reports

Crizotinib API Market - Global Forecast 2025-2030 - Product Image

Crizotinib API Market - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Crizotinib (CAS 877399-52-5) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Crizotinib (CAS 877399-52-5) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer - Pipeline Insight, 2025 - Product Image

Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Lung Cancer Drugs Market Report 2025 - Product Image

Lung Cancer Drugs Market Report 2025

  • Report
  • 175 Pages
  • Global
From
ALK Positive Non-Small Cell Lung Cancer- Pipeline Insight, 2025 - Product Image

ALK Positive Non-Small Cell Lung Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.